A Phase 3 interventional study of Lurbinectedin (PM01183) and Pegylated liposomal doxorubicin (PLD) in Ovarian Cancer, sponsored by PharmaMar. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.
Sponsored by PharmaMar · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.
Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 132nd largest by enrollment of the 1,498 interventional ones that give a count, is one of 68 that started in 2015, is one of 103 in phase 3, and was the 885th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.
Browse Ovarian Neoplasms studies →278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Israel, Taiwan
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+
GE Healthcare · Sites in United States, Sweden
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,779 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 769 · Phase 2 718 · Phase 3 114 · Phase 4 8
First in 1980; this study’s year is marked. 68 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 442 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 1,498 interventional studies, 176 across the 195 observational. Of the 1,209 that completed or were terminated, 445 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
713 of 1,779 have an industry lead sponsor. The 10 most frequent:
PharmaMar is the lead sponsor of 50 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
PharmaMar has 4 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
162 of the studies in Ovarian Neoplasms with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05281471Phase 3Genelux CorporationEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | 2026-12 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
Add all 162 to your calendar (.ics) → With an account.
Among the 1,779 studies in Ovarian Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lurbinectedin (PM01183)
Drug: Lurbinectedin (PM01183)
pegylated liposomal doxorubicin OR topotecan
Drug: Pegylated liposomal doxorubicin (PLD) · Drug: Topotecan
Progression-free Survival by Independent Review Committee
The primary endpoint was PFS by IRC assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.
Time frame: Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years
Progression-free Survival by Investigator's Assessment
The primary endpoint was PFS by Investigator's Assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.
Time frame: Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years
Overall Survival (OS)
Calculated from the date of randomization to the date of death (death event) or last contact (in this case, survival was censored on that date).
Time frame: From the date of randomization to the date of death or last contact, up to 12 months after last patient inclusion, for a maximum of up to 3 years
Overall Response Rate (ORR) by Independent Review Committee
Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.
Time frame: At baseline and every eight weeks from randomization until evidence of PD, assessed up to 3 years
Overall Response Rate by Investigator's Assessment
Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.
Time frame: At baseline and every eight weeks from randomization until evidence of PD, assessed up to 3 years
Duration of Response by Independent Review Committee
Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.
Time frame: The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years
Duration of Response by Investigator's Assessment
Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.
Time frame: The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years
Best Response According to Tumor Marker Evaluation (CA-125)
Best response according to tumor marker evaluation (CA-125): defined as the best response obtained according to GCIG criteria. Tumor marker assessments were performed at baseline and every eight weeks from randomization until evidence of PD. Progression based on serum CA-125 levels was defined on the basis of a progressive serial elevation of serum CA-125 according to: A. Patients with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart or B. Patients with elevated CA-125 before treatment, which never normalizes, must show evidence of CA-125 greater than, or equal to, 2 times the nadir value on 2 occasions at least 1 week apart or C. Patients with CA-125 in the reference range before treatment must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart.
Time frame: At baseline and every eight weeks from randomization until evidence of PD, up to 3 years
First randomization/first study treatment administration took place on 26JUN2015. The cutoff date for results was 12OCT2018. 534 patients were screened; 442 were randomized at 83 sites/12 countries. 10 patients did not receive the study treatment.
| Milestone | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Started | 221 | 221 |
| Completed | 0 | 0 |
| Not completed | 221 | 221 |
| Withdrew: Non-treatment-related ae | 8 | 8 |
| Withdrew: Progressive disease | 152 | 135 |
| Withdrew: Death | 11 | 3 |
| Withdrew: Physician decision | 8 | 17 |
| Withdrew: Other reason not specified | 3 | 1 |
| Withdrew: Symptomatic deterioration | 13 | 19 |
| Withdrew: Treatment-related ae | 10 | 14 |
| Withdrew: Withdrawal by subject | 14 | 16 |
| Withdrew: Not treated | 2 | 8 |
The primary endpoint was PFS by IRC assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.
| months | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Progression-free Survival by Independent Review Committee | 3.5 (2.1 to 3.7) | 3.6 (2.7 to 3.8) |
The primary endpoint was PFS by Investigator's Assessment, defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient received further antitumor therapy or was lost to follow-up before PD, PFS was censored at the date of last tumor assessment before the date of subsequent antitumor treatment.
| months | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Progression-free Survival by Investigator's Assessment | 3.7 (3.6 to 3.9) | 3.7 (3.5 to 4.0) |
Calculated from the date of randomization to the date of death (death event) or last contact (in this case, survival was censored on that date).
| months | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Overall Survival (OS) | 11.4 (9.0 to 14.2) | 10.9 (9.3 to 12.5) |
Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.
| Participants | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Complete response | 3 | 3 |
| Partial response | 29 | 25 |
| Stable disease | 90 | 97 |
| Progressive disease | 83 | 72 |
| Unknown | 16 | 24 |
Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum; Overall Response (OR)=CR+PR.
| Participants | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Complete response | 3 | 2 |
| Partial response | 32 | 35 |
| Stable disease | 107 | 94 |
| Progressive disease | 63 | 68 |
| Unknown | 16 | 22 |
Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.
| months | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Duration of Response by Independent Review Committee | 4.0 (1.9 to 5.7) | 3.7 (3.6 to 7.2) |
Duration of response (DR): calculated from the date of first documentation of response per RECIST v.1.1 (CR or PR, whichever came first) to the date of documented PD or death. The censoring rules defined above for PFS were used for duration of response. Best antitumor response defined as the best response obtained according to RECIST v.1.1. Tumor assessment were performed at baseline and every 8 weeks from randomization until evidence of PD. Patients who discontinued treatment without PD continued with assessments. Antitumor activity was assessed using the RECIST v.1.1 by the appropriate method \[computed tomography scan or magnetic resonance imaging\]: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR)=CR+PR.
| months | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Duration of Response by Investigator's Assessment | 4.3 (3.6 to 5.8) | 3.7 (3.2 to 5.6) |
Best response according to tumor marker evaluation (CA-125): defined as the best response obtained according to GCIG criteria. Tumor marker assessments were performed at baseline and every eight weeks from randomization until evidence of PD. Progression based on serum CA-125 levels was defined on the basis of a progressive serial elevation of serum CA-125 according to: A. Patients with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart or B. Patients with elevated CA-125 before treatment, which never normalizes, must show evidence of CA-125 greater than, or equal to, 2 times the nadir value on 2 occasions at least 1 week apart or C. Patients with CA-125 in the reference range before treatment must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart.
| Participants | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Complete response | 13 | 3 |
| Partial response | 33 | 29 |
| Stable disease | 95 | 94 |
| Progressive disease | 17 | 16 |
| Unknown | 15 | 23 |
Collected over Participants were assessed through study completion, approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lurbinectedin | 170/219 (77.6%) | 92/219 (42%) | 212/219 (96.8%) |
| Control (PLD or Topotecan) | 171/213 (80.3%) | 85/213 (39.9%) | 211/213 (99.1%) |
| Event | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 24/219 | 21/213 |
| Febrile neutropeniaBlood and lymphatic system disorders | 14/219 | 12/213 |
| NeutropeniaBlood and lymphatic system disorders | 11/219 | 13/213 |
| AnaemiaBlood and lymphatic system disorders | 8/219 | 12/213 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/219 | 11/213 |
| VomitingGastrointestinal disorders | 10/219 | 4/213 |
| AscitesGastrointestinal disorders | 4/219 | 7/213 |
| NauseaGastrointestinal disorders | 7/219 | 4/213 |
| Abdominal painGastrointestinal disorders | 6/219 | 6/213 |
| SepsisInfections and infestations | 5/219 | 1/213 |
| Event | Lurbinectedin | Control (PLD or Topotecan) |
|---|---|---|
| NauseaGastrointestinal disorders | 156/219 | 92/213 |
| FatigueGeneral disorders | 133/219 | 113/213 |
| NeutropeniaBlood and lymphatic system disorders | 73/219 | 89/213 |
| VomitingGastrointestinal disorders | 87/219 | 58/213 |
| AnaemiaBlood and lymphatic system disorders | 57/219 | 77/213 |
| Abdominal painGastrointestinal disorders | 74/219 | 52/213 |
| ConstipationGastrointestinal disorders | 72/219 | 61/213 |
| Mucosal inflammationGeneral disorders | 22/219 | 68/213 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 3/219 | 51/213 |
| Decreased appetiteMetabolism and nutrition disorders | 51/219 | 47/213 |
| Age, Categorical(Participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 126 | 141 | 267 |
| >=65 years | 95 | 80 | 175 |
| Age, Continuous(years) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| Median | 63.0 (25 to 85) | 59.0 (28 to 87) | 61.0 (25 to 87) |
| Sex: Female, Male(Participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| Female | 221 | 221 | 442 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 2 | 8 |
| White | 192 | 201 | 393 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 21 | 14 | 35 |
| Region of Enrollment(participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| United States | 39 | 40 | 79 |
| Romania | 11 | 11 | 22 |
| Spain | 40 | 46 | 86 |
| United Kingdom | 17 | 14 | 31 |
| Austria | 3 | 4 | 7 |
| Belgium | 21 | 19 | 40 |
| Bulgaria | 5 | 5 | 10 |
| Czechia | 5 | 5 | 10 |
| France | 19 | 12 | 31 |
| Hungary | 9 | 14 | 23 |
| Italy | 47 | 47 | 94 |
| Serbia | 5 | 4 | 9 |
| Body mass index(Participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| ≤20 kg/m^2 | 26 | 37 | 63 |
| 20-25 kg/m^2 | 82 | 84 | 166 |
| 25-30 kg/m^2 | 62 | 51 | 113 |
| >30 kg/m^2 | 50 | 49 | 99 |
| Unknown | 1 | 0 | 1 |
| ECOG PS(Participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| PS 0 | 126 | 123 | 249 |
| PS 1 | 87 | 94 | 181 |
| PS 2 | 8 | 4 | 12 |
| Primary site(Participants) | Lurbinectedin | Control (PLD or Topotecan) | Total |
|---|---|---|---|
| Ovarian | 196 | 195 | 391 |
| Fallopian | 11 | 13 | 24 |
| Peritoneal | 14 | 13 | 27 |
15 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of May 2015, a primary completion of Oct 2018 and a completion of Oct 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2020, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183